Comment from Bexorg Inc.

Summary: Bexorg, a translational research company, supports the draft guidance for using New Approach Methodologies (NAMs) in drug development, particularly for CNS programs. They argue that the guidance's focus on "fit-for-purpose" validation and a weight-of-evidence framework is essential for incorporating human-relevant data to reduce high clinical failure rates.